HuiSheng Biology

HuiSheng Biopharmaceutical Co., Ltd. operates as a biopharmaceutical enterprise focused on the treatment of diabetes and its associated complications. Established in 2019 in Jilin, China, the company is a subsidiary of the Sihuan Pharmaceutical Holdings Group. The firm's activities encompass the development and manufacturing of both biological and chemical drug products.

The company is led by CEO Haiyan Cao, who brings over two decades of experience in biopharmaceutical product development, clinical guidance, and project management to the role. HuiSheng Bio-pharmaceutical has established a significant presence in Jilin, with additional branches in Changchun and Beijing. As of 2022, the company's infrastructure supports an annual production capacity of 50 million units of insulin and it holds 10 patents. Its product pipeline is extensive, with more than 40 products addressing diabetes and its complications. These products fall into several categories, including insulin and its analogs, GLP-1 analogs, biguanides, DPP-4 inhibitors, SGLT-2 inhibitors, and glinides.

HuiSheng Biopharmaceutical's business model is geared towards serving the needs of patients with diabetes by developing a comprehensive range of therapeutic options. The company has secured funding from investors such as Grand Flight Investment, China Life Capital, and TONGHE DINGTAI INVESTMENT MANAGEMENT LIMITED to support its research and development efforts. The company has received venture capital backing, completing a Series A1 funding round in January 2023, which raised $83.2 million, and a Series A round in June 2022. This financial support enables the company to advance its diverse product pipelines and strengthen its position in the diabetes care market.

The company's product portfolio includes items like Prourogliflozin Tablets, Degludec Insulin, Degludec & Aspart Insulin, and Aspart Insulin, alongside various active pharmaceutical ingredients (APIs) and intermediates. By focusing on a specialized area of medicine and developing a wide array of products, HuiSheng Biopharmaceutical aims to provide comprehensive solutions for individuals managing diabetes. The company's structure and strategic investments reflect a commitment to addressing the complexities of diabetes treatment through a combination of biological and chemical pharmaceutical approaches. Keywords: Biopharmaceuticals, diabetes treatment, insulin analogs, GLP-1 analogs, DPP-4 inhibitors, SGLT-2 inhibitors, metabolic diseases, pharmaceutical manufacturing, clinical development, drug discovery, endocrine disorders, chronic illness therapies, biotherapeutics, pharmaceutical research, Jilin China, Haiyan Cao, Sihuan Pharmaceutical, Grand Flight Investment, China Life Capital, TONGHE DINGTAI INVESTMENT MANAGEMENT